MI-mAbs

The French demonstrator of #immunotherapy #antibodies for #cancer, #inflammation & #immunodeficiency

[MI-mAbs @MI_mAbs]

The pre-industrial demonstrator @MIMABS announce the start of operations of MImAbs SAS, an #immunotechnology company specializing in generation and validation of therapeutic #antibodies against #cancer and inflammatory diseases https://t.co/QsmNUxTZqE @univamu @RegionSudInvest

[MI-mAbs @MI_mAbs]

Le démonstrateur préindustriel @MimAbs donne naissance à MImAbs SAS: société de service en #immunotechnologie spécialisée dans la génération et la validation de nouveaux #anticorps thérapeutiques https://t.co/aZ0XRWH2yZ @univamu @RegionSudInvest

[MI-mAbs @MI_mAbs]

An integrated analysis of #BispecificAntibodies in complex with #antigens (SEC/MALS, native MS, MS-based footprinting, epitope characterization) can provide molecular details of binding mechanisms #GuodongChen et al. @an_chem https://t.co/496Krrh4NB

[MI-mAbs @MI_mAbs]

DLL3/CD3 #BispecificAntibody specifically redirects T cells to lyse #SCLC cells expressing Delta-like ligand 3 and leads to #tumor regression in an in vivo model #SusanneHipp et al. @CCR_AACR https://t.co/SXeqG4n5hL

[MI-mAbs @MI_mAbs]

Accelerate the development of a #MonoclonalAntibody at the time of #COVID19 pandemic. Here the key sequence covering from lead identification to phase 1 clinical study @Vir_Biotech @NatureBiotech https://t.co/4f3fVJQJ1P

[Marseille Immunopole @Immunopole]

The @US_FDA granted accelerated approval to #Trodelvy #sacituzumabgovitecan-hziy, the first #AntibodyDrugConjugate that targets Trop-2, for treatment of #mTNBC #BreastCancer https://t.co/insakHD5ol

[MI-mAbs @MI_mAbs]

A tripartite β-lactamase enzyme assay in #Ecoli could assess aggregation propensity of #antibody fragments early in #DrugDevelopment and improve #antibody #developability | #DavidCLowe #DavidJBrockwell et al. @NatureComms | https://t.co/uJeKZuPoLJ

[MI-mAbs @MI_mAbs]

Following the government’s stipulations to limit the spread of #Covid19, @MI_mAbs laboratories have closed.
Nevertheless, part of the team is still on board and will be available to answer to your questions. https://t.co/9uuOXeOatW

[MI-mAbs @MI_mAbs]

We will participate (digitally) at #BioSpringEurope next week. Please contact us to organize a (virtual!) meeting during this event. https://t.co/zu8GUw1TVO

[MI-mAbs @MI_mAbs]

#BIOEuropeSpring will be delivered as a fully #digital event, contact @Mimabs's team to organize a (virtual!) meeting during this event ! https://t.co/zu8GUw1TVO

[MI-mAbs @MI_mAbs]

Come and meet us at 4th Annual @marketsmarkets
Next Gen #ImmunoOncology Congress https://t.co/6ndzyxp2df

[Leem @LeemFrance]

CP : médicaments de thérapie innovante : une filière dynamique et bien implantée en France avec 36 sociétés. => https://t.co/xrWDti0RAS

[MI-mAbs @MI_mAbs]

One of the 2019 highlights of @US_FDA #DrugApprovals: 3 new #AntibodyDrugConjugates, leading to a total of 7 FDA-approved #ADCs, all for the treatment of #cancer. Full analysis of 2019 approvals by #BdelaTorre & @Falbericio @Molecules_MDPI | https://t.co/WqAXlwRIR1

[MI-mAbs @MI_mAbs]

To avoid toxicity of #pyrrolobenzodiazepine #IVlahov et al made a pro-PBD2 #prodrug that becomes active inside target cells; subnanomolar activity + good specificity when conjugated to folate. What about in an #antibodydrugconjugate? #BioorgMedChemLett | https://t.co/eDRVRJywat

[MI-mAbs @MI_mAbs]

L'équipe de @MIMABS est fière d’avoir participé au projet en gérant la #production et l'#humanisation de l'#anticorps anti-#CD146

[SATT Sud-Est @SATTse_]

💊 #biotech @syndivia in-licenses novel #antibody against #tumor specific form of CD146 from #C2VN #TechTransfer by @SATTse_ 👍 | @ReseauSATT

https://t.co/h8qDEoq4tn

[MI-mAbs @MI_mAbs]

#MIday #lungcancer, interesting conference in Marseille
@barlesi @EricVivier1 @JeromeGalon @Immunopole

[Marseille Immunopole @Immunopole]

#MIDay #LungCancer "In the #clinic, the bigger the team, the higher the chances of success for #patients" @Barlesi
@univamu @GustaveRoussy @immunopole

[Made in Marseille @MadeMarseille]

🔬 #Marseille est une des capitales mondiales de la recherche contre le #cancer, en particulier en immuno-oncologie. Pour le #MIday, jeudi, un comité d’experts répond au public et décortique 10 idées reçues sur le cancer du poumon. Les détails ➡️ https://t.co/kx15hEmdlv

[MI-mAbs @MI_mAbs]

#WebinarReplay Want to learn about #ADCs? “State of the art ADC validation” our webinar replay is available here : https://t.co/pHxAPZz2ik @MI_mAbs

[MI-mAbs @MI_mAbs]

Come and meet us at Toulouse Onco Week and do not miss @MI_mAbs 's presentation this Wednesday ! #TOW2020 | @TOW_2020 https://t.co/BMGXX4WS9K